Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

AI Summary

A Dutch court barred Merck from selling a subcutaneous version of Keytruda in several European countries in a patent dispute with Halozyme. The article also notes Enliven's anticipated leukemia trial, an Insmed executive's departure, and venture funding for two startups.

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.